Company intelligence / Profile preview

Selzy

Raleigh, North Carolina, United Statesselzy.com ↗

Ownership: Private
Employees: ~4
Development stage: Commercial

Overview

SelSym’s lead product, SymClot, is an innovative synthetic platelet designed to improve hemorrhage control and wound healing. The company’s Hemostatic Healing Hydrogels address bleeding management and wound care. As of early 2023, the company was preparing for Phase II STTR funding to support formulation/testing ahead of an IND submission.

Therapeutic areas: DermatologyHematology
Modalities: Synthetic platelet technologyHydrogel-based drug delivery therapyProtein (for synthetic platelet mimics)
Industry: Biotech

Beyond the preview

Go deeper on Selzy.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Selzy.

Explore the full profile